KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Core Insights - Merck announced that the combination of KEYTRUDA® (pembrolizumab) and Padcev® (enfortumab vedotin-ejfv) significantly improved patient outcomes in muscle-invasive bladder cancer (MIBC) [1] Efficacy Results - The combination therapy reduced the risk of event-free survival (EFS) events by 47% compared to neoadjuvant chemotherapy and surgery [1] - Additionally, it reduced the risk of death by 35% when administered before and after surgery in patients eligible for cisplatin-based chemotherapy [1]